**EVA-PCD FUNCTIONAL PROFILE**

**Patient: Doe, Jane Assay Date: 3/28/2018**

**Dx: Cervical Assay Quality:**

**Prior Rx: Untreated Report Date: 1/10/2019**

**Physician: Dr. Doolittle Specimen Number: 180328.01**

**Ex Vivo Ex Vivo Ex Vivo**

**Activity Synergy Interpretation**

**Drug** Response Expectation

Compared with Database

**▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬▬**

**SINGLE DRUG DOSE EFFECT ANALYSIS**

Afatinib (HER 1,2,4) Inactive Lower

Alpelisib (PI3K) Active \*\* Mapping ???

AZD-4547 (FGFR) Active \*\* Mapping ???

CB-839 (Glutaminase) (Glutaminase) Active \*\* Mapping ???

Crizotinib (ALK/MET/ROS) Moderately Active Average

Dactolisib (PI3K/mTOR) Active \*\* Mapping ???

Dasatinib (SRC) Inactive Lower

Doxorubicin Intermediate Average

Everolimus (mTOR) Active \*\* Mapping ???

Gefitinib (EGFR) Inactive Lower

Imatinib (c-ABL/c-KIT/PDGFR) Resistant Lower

JQ1 (MYC) Active \*\* Mapping ???

Lapatinib (HER1,2) Inactive Lower

Olaparib (PARP) Inactive Lower

Palbociclib (CDK4/6) Moderately Active Average

Pazopanib (VEGF/PDGFR/c-KIT) Active \*\* Mapping ???

Phenformin (Mitochondrial) Resistant Lower

Selumetinib (MEK) Active \*\* Mapping ???

Tazemetostat (EZH2) Inactive Lower

Vorinostat (HDAC) Active \*\* Mapping ???

**MULTIPLE DRUG DOSE EFFECT ANALYSIS**

CB-839 (Glutaminase) & Everolimus Active Partial Synergy \*\* Mapping ???

Cisplatin & Doxorubicin Intermediate N/A Average

Cisplatin & Gemcitabine Intermediate N/A Average

Cisplatin & Gemcitabine & 5-Fu Sensitive N/A Higher

Cisplatin & Taxol Sensitive N/A Higher

Cisplatin & Topotecan Sensitive N/A Higher

Cytoxan & Doxorubicin Sensitive N/A Higher

Cytoxan & Taxol Resistant N/A Lower

Everolimus & Phenformin Inactive Antagonism Lower

Tazemetostat & Vorinostat Inactive Antagonism Lower

**DATA ANALYSIS:**

Laboratory results represent only one part of the overall determination of therapy for patients and do not

guarantee outcomes nor indicate the specific drugs that should be used in a particular patient.

\* The following compounds serve as in vitro surrogates for their respective drug classes, e.g., Cytoxan: =

Cyclophosphamide, Ifosfamide, Melphalan, Chlorambucil and related mustard alkylators; Cisplatin: =

Carboplatin; Doxorubicin: = Daunorubicin and Idarubicin; Trimetrexate: = Methotrexate; 5Fu + Interferon: =

**Ex Vivo best regimen (EVBR®) would be Irinotecan +/ -Cisplatin.**

Robert A. Nagourney, MD

Laboratory and Medical Director

Rational Therapeutics